Oil prices hold sharp losses with focus on secondary India tariffs
SOUTH SAN FRANCISCO - CytomX Therapeutics, Inc. (NASDAQ:CTMX), a biopharmaceutical company specializing in the development of probody therapeutics, has set the price for its public stock offering at $1.30 per share. The company is offering 76,923,076 shares, aiming to raise approximately $100 million in gross proceeds before deductions for underwriting discounts and commissions, as well as other expenses related to the offering. According to InvestingPro data, the company currently maintains a strong financial health score of 3.2 out of 5, with the notable advantage of holding more cash than debt on its balance sheet.
The closing of the offering is anticipated for Tuesday, subject to standard closing conditions. CytomX intends to allocate the net proceeds towards advancing its research and development projects, as well as for general corporate purposes and working capital needs. This capital raise comes at a crucial time, as InvestingPro analysis indicates the company has been quickly burning through cash, despite achieving profitability over the last twelve months with a revenue of $138.1 million. For deeper insights into CytomX’s financial health and future prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Several investment firms participated in the offering, including Longitude Capital, OrbiMed, Venrock Healthcare Capital Partners, Vivo Capital, RTW Investments, and a prominent investment management firm. Jefferies and Piper Sandler are serving as the joint book-running managers for the offering.
CytomX’s securities are being offered through an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on August 9, 2024. Further details about the offering will be available in a prospectus supplement, along with the accompanying prospectus, which will be filed with the SEC.
The company’s innovative approach focuses on creating conditionally activated, masked biologics that localize to the tumor microenvironment, aiming to produce safer, more effective cancer treatments. CytomX’s pipeline includes a variety of therapeutic candidates such as antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators like cytokines. Its clinical-stage pipeline features CX-2051, an ADC targeting EpCAM-expressing epithelial cancers, and CX-801, a masked interferon alpha-2b cytokine.
CytomX has established collaborations with several leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, to further its vision of revolutionizing cancer therapy.
The company cautions that statements regarding the offering’s timing, completion, and anticipated proceeds are forward-looking and are subject to various risks and uncertainties. These may include market conditions and other factors that could impact the completion of the offering on the expected terms or at all.
This news is based on a press release statement from CytomX Therapeutics, Inc.
In other recent news, CytomX Therapeutics reported robust financial results for the fourth quarter of 2024, with revenue reaching $138.1 million, significantly surpassing the forecasted $12.24 million. This impressive performance is attributed to successful collaborations with major partners like Bristol Myers Squibb, Moderna, Astellas, and Regeneron. CytomX also extended its cash runway to the second quarter of 2026, ensuring financial stability. In partnership with Moderna, CytomX unveiled promising preclinical data for a new cancer therapy, an mRNA-encoded masked IL-12 molecule, which could potentially overcome the limitations of IL-12’s inflammatory toxicity. Additionally, Piper Sandler initiated coverage on CytomX with an Overweight rating and a price target of $2.50, citing the company’s progress in clinical trials and strategic partnerships. CytomX is currently enrolling participants for Phase I studies of its drug candidates CX-2051 and CX-801, with initial results expected in 2025. These recent developments highlight CytomX’s strategic positioning in the oncology market and its ongoing efforts to advance its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.